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Available online 16 February 2016Background: The Universal Deﬁnition for type 5 myocardial infarction (MI) applies to coronary artery bypass
grafting (CABG), while MIs for other cardiac surgery are not speciﬁcally deﬁned. We assessed whether elevated
high-sensitivity troponin (hs-TnT), with electrocardiogram (ECG) changes and/or new wall motion abnormali-
ties on echocardiography as deﬁned by theUniversal Deﬁnition, predictedmortality and/ormorbidity after aortic
valve replacement (AVR) (n = 219).
Methods: Consecutive patients with isolated AVR performed during July 2010–December 2012 and followed-up
for 2.3± 0.8 years. Hs-TnTwasmeasured 12–24 h post-operatively. ECG and/or echocardiographic changes with
hs-TnT N140 ng/L (10 times 99th percentile upper reference limit and N500 ng/L (10 times the coefﬁcient of var-
iation of 10% for 4th generation troponin T applied to hs-TnT) were pre-speciﬁed as the criteria for MI diagnosis.
Results: There were 9.1% (20) and 3.7% (8) patients with ECG and/or echocardiographic changes and hs-
TnT N 140 ng/L and hs-TnT N 500 ng/L respectively. Neither criterion was independently associated with
30-day mortality (2.7%). Hs-TnT N 500 ng/L and ECG and/or echocardiographic changes was independently
associated with mortality (5.5%) during follow-up, hazards ratio 5.23, 95% conﬁdence interval 1.09–25.2,
p = 0.039. Hs-TnT per 100 ng/L as a continuous parameter was independently associated with 30-day
mortality, mortality during follow-up and composite morbidity.
Conclusion: The Universal Deﬁnition of MI, using 10 times the URL for the 4th generation troponin T and 35
times the URL for hs-TnT with a cutpoint of N 500 ng/L with ECG and/or echocardiographic changes, inde-
pendently predictedmedian termmortality after AVR. Hs-TnT as a continuous parameter was independent-
ly associated with mortality at both time points and morbidity.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Mortality1. Introduction
The 2012 Third Universal Deﬁnition deﬁnes type 5 myocardial in-
farction (MI) after coronary artery bypass grafting (CABG) as requiring
the dual criteria of biomarker rise, preferably troponin, N10 times 99th
percentile upper reference limit (URL) from a normal pre-operative
level, and new signs of infarction on the electrocardiogram (ECG),terest.
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liability and freedom from bias
. This is an open access article underechocardiogram, cardiacmagnetic resonance imaging (MRI), and/or by-
pass graft occlusion on coronary angiography [1]. The Deﬁnition also
suggests applying the above deﬁnition to other cardiac procedures,
while acknowledging that biomarker rise is signiﬁcantly higher for com-
bined CABG and valve surgery than CABG alone, and with on-pump
compared to off-pump CABG [1–3]. The deﬁnition is based on patho-
physiological criteria and not a deﬁnition that correlateswith prognosis.
Despite these recommendations, there is a paucity of literature
around how to deﬁne MI for valve surgery. Studies assessing troponin
levels after cardiac surgery are predominantly based on CABG, [4–7]
and the few studies looking speciﬁcally at troponin levels after valve
surgery have found different thresholds to those reported for CABG
[8–10].
High-sensitivity troponins can detect lower troponin levels [11,12]
but have not been investigated in this context. We aimed to assess the
diagnostic and prognostic utility of high-sensitivity troponin T (hsTnT)
after isolated aortic valve replacement (AVR) using the Universal
Deﬁnition of MI.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Patient cohort, clinical characteristics and outcomes
All patients undergoing isolated AVR without concomitant valve or
coronary surgery at Auckland City Hospital during July 2010 to
December 2012 were retrospectively identiﬁed. Patients with elevated
pre-operative hsTnT levels N14 ng/mL were excluded. Clinical charac-
teristics and outcomes were prospectively collected in computerized
databases for analyses. The Society of Thoracic Surgeon's (STS) deﬁni-
tions were used for pre-operative characteristics [13]. The Canadian
Cardiovascular Society Classiﬁcation (CCS) and the New York Heart As-
sociation Functional Classiﬁcation (NYHA) were used to grade angina
and heart failure respectively. Valve stenosis or regurgitation needed
to be at least moderate in severity. The deﬁnition of active infective en-
docarditis required that at the time of surgery, a course of intravenous
antibiotics had yet to be commenced or completed. Renal function
was calculated as the estimated glomerular ﬁltration rate (eGFR)
using the Modiﬁcation of Diet in Renal Disease (MDRD) equation and
the pre-operative serum creatinine measurement. EuroScore, [14]
EuroScore II [15] and STS score's AVR Model [13] were calculated.
The pre-speciﬁed outcomes for analyses were mortality within
30 days, mortality during follow-up and composite morbidity, as de-
ﬁned by the STS score, [13] which includes permanent stroke (acute
neurological deﬁcit N24 h due to cerebral blood supply disturbance),
renal failure (new dialysis requirement or increase of creatinine level
to N4.0mg/dL and N3 times last pre-operative level), prolonged ventila-
tion N24 h, deep sternal wound infection and return to theatre for any
reason. Mortality data were checked against New Zealand's National
Registry up till 30 June 2014.
2.2. Troponin assays and criteria for myocardial infarction
Hs-TnT assay (Roche Elecsys) was introduced to Auckland City
Hospital in July 2010, and has a 99th percentile URL of 14 ng/L [11].
The cutpoint used for the previous 4th generation troponin T with a
10% coefﬁcient of variation (0.03 ng/ml) when applied to the hs-TnT
assay is 50 ng/l [12]. Hs-TnT was routinely measured 12–24 h after sur-
gery, and the highest level was used if measuredmore than once during
this time. Two cutpoints of 140 ng/L and 500 ng/Lwere pre-speciﬁed for
analyses in accordance to the above thresholds and the universal
deﬁnition's recommendation of 10 times 99th percentile URL for the di-
agnosis of type 5 MI [1]. Hs-TnT was not routinely measured pre-
operatively, and we excluded patients with a new MI diagnosis or any
elevated hs-TnT N 14 ng/L measurements pre-operatively during the
same admission as the AVR operation.
ECGs were routinely performed recorded multiple times pre- and
post-operatively while echocardiography was performed routinely
intra-operatively after aortic valve implantation as a baseline for future
assessments, and repeated when clinically indicated. New Q-waves or
new left bundle branch block (LBBB) on ECG, and/or new regional
wall motion abnormalities on echocardiography were independently
assessed by two authors (TKMWandHDW) blinded to outcomes, in ac-
cordance to the criteria of the Universal deﬁnition [1]. The prognostic
utility of dual criteria of hs-TnT elevation and ECG and/or echocardio-
graphic criteria, as well as these criteria individually, was compared.
2.3. Statistical analyses
Continuous and categorical variables are presented as mean
(standard deviation) and percentage (frequency) respectively, Mann–
Whitney U test and Fisher's exact testwere used for univariate analyses.
Survival analyses were performed with Kaplan–Meier curves and log-
rank (Mantel-Cox) test. The pre-speciﬁed hs-TnT cutpoints of
140 ng/L and 500 ng/L with or without ECG and/or echocardiographic
changes were used for analyses. Variables with P b 0.10 in univariateanalyses were incorporated into multivariable analyses of outcomes,
using logistic regression to calculate odds ratios (OR) or Cox proportional
hazards regression used to calculate hazards ratios (HR). Each potential
MI criteria was individually added to the models of post-operative out-
comes to see whether they predicted these outcomes. Also receiver-
operative characteristics (ROC) analysis was used to calculate c-statistic
and 95% conﬁdence interval (CI) as well as identifying the optimal cut-
point with maximum sensitivity × speciﬁcity. All tests were two-tailed
and P b 0.05 deemed statistically signiﬁcant. SPSS (Version 17.0, SPSS
Inc., Chicago, IL, USA) and Prism (Version 5, GraphPad Software, San
Diego, CA, USA) were used for analyses. Ethics approval was obtained
from, Auckland City Hospital's research ofﬁce Ethics Committee.
3. Results
3.1. Baseline characteristics
A total of 219patients underwent isolated AVR atAucklandCityHos-
pital, New Zealand over the 2.3 year study period (386 patient years).
Table 1 shows the baseline characteristics. The mean age was 67.5 ±
14.9 years and 33.3% (73) were female. Previous valve surgery and
CABGhad been performed in 7.3% (16) and 7.3% (16) of patients respec-
tively. Underlying aortic valve dysfunction was isolated aortic stenosis
in 67.0% (146), isolated aortic regurgitation 21.6% (47) and both in
11.5% (25). The mean EuroScore, EuroScore II and STS AVR Scores
were 8.6% ± 8.1%, 3.1% ± 3.3% and 2.9% ± 2.9% respectively.
3.2. Operative outcomes
Blood cardioplegia was used for myocardial protection. There were
14.7%, 63.3% and 22.0% patients who received anterograde, retrograde
and dual cardioplegia delivery routes respectively. Warm induction
was given at a temperature of 32 °C in 11.9% and the remaining patients
were given cold induction at a temperature of 4 °C. Secondary analyses
did not identify cardioplegia variables to independently inﬂuence hs-
TnT levels or adverse outcomes.
Table 2 lists operative variables and post-operative outcomes. Me-
chanical valves were implanted in 31.1% (68) and bioprosthetic valves
in 68.9% (151). Median and lower-upper quartiles of hs-TnT were 360
(258–536) ng/L measured at 16.7 ± 5.9 h post-operatively. For the
pre-speciﬁed hs-TnT cutpoints, 98.6% (216) had hs-TnT N 140 ng/L
and 31.1% (68) had hs-TnT N 500 ng/L.
All 219 patients had post-operative ECGs performed with 8.7% (19)
developing new Q-waves or new LBBB. Echocardiograms were per-
formed in 31.5% (69) of patients with one showing a new regional
wall motion abnormality. Therefore, 9.1% (20) patients fulﬁlled the
ECG and/or echocardiographic criteria for diagnosis of MI. For the pre-
speciﬁed hs-TnT cutpoints, 9.1% (20) had hs-TnT N 140 ng/L and
ECG and/or echocardiographic criteria, while 3.7% (8) had hs-
TnT N 500 ng/L and ECG and/or echocardiographic criteria.
Thirty-day mortality was 2.7% (6). Composite morbidity occurred in
20.5% (45) including post-operative stroke in 1.4% (3), prolonged venti-
lation N24 h 13.7% (30) and return to theatre for any cause in 6.8%
(Table 2). Mean hospital stay post-operatively was 8.9 ± 5.1 days.
Follow-up mortality was 5.5%.
3.3. Receiver-operating characteristic analyses
Results of ROC analyses are shown in Table 3. The dual criteria of hs-
TnT as a continuous parameter and ECG and/or echocardiographic
criteria detected 30-day mortality with c-statistic and 95% conﬁdence
intervals of 0.816 (0.521–1.00); superior to isolated hs-TnT or isolated
ECG and/or echocardiographic criteria. The best cutpoint on the ROC
curve for isolated hs-TnT rise predicting 30-day mortality was
630 ng/L with a c-statistic of 0.746 (0.523–0.969). This elevation oc-
curred in 9.1% (20) of patients. Neither of the pre-speciﬁed cutpoints
Table 1
Baseline characteristics.
Demographics
Age, years 67.5 (14.9)
Female 33.3% (73)
Ethnicity
New Zealand European 75.8% (166)
Maori or Paciﬁc 16.9% (37)
Other 7.3% (16)
Body mass index, kg/m2 29.7 (6.2)
Body surface area, m2 1.94 (0.26)
Presentation
New York Heart Association Class
1 23.7% (52)
2 48.9% (107)
3 18.7% (41)
4 8.7% (19)
Canadian Cardiovascular Society Class IV 2.3% (5)
Syncope 2.7% (6)
Critical pre-operative state 3.7% (8)
Inpatient urgent operation 46.1% (101)
Past medical history
Previous cardiac surgery 14.6% (32)
Valve surgery 7.3% (16)
Coronary artery bypass grafting 7.3% (16)
Congestive heart failure 16.0% (35)
Myocardial infarction 8.7% (19)
Atrial ﬁbrillation 21.5% (47)
Diabetes 21.0% (46)
Diabetes on insulin 5.0% (11)
Hypertension 54.8% (120)
Hypercholesterolaemia 67.1% (147)
Current smoker 9.1% (20)
Smoking history 54.8% (120)
Active infective endocarditis 4.6% (10)
Stroke 5.0% (11)
Extracardiac arteriopathy 6.8% (15)
Chronic pulmonary disease 17.8% (39)
Pulmonary hypertension, ≥31 mm Hg 10.5% (23)
Dialysis 2.3% (5)
Investigations
Ejection fraction
Normal, N50% 62.1% (136)
Mild/moderate impairment, 30–50% 33.3% (73)
Severe impairment, b30% 4.6% (10)
Aortic stenosis 78.1% (171)
Aortic regurgitation 32.9% (72)
Mitral stenosis 0.9% (2)
Mitral regurgitation 7.3% (16)
Tricuspid regurgitation 3.7% (8)
Left main artery ≥ 50% stenosis
Main coronary vessels ≥ 50% stenosis* 2.3% (5)
0 84.5% (185)
1 8.2% (18)
2 1.4% (3)
3 5.9% (13)
Creatinine clearance, mL/min 85 (40)
Risk score
EuroScore 8.6% (8.1%)
EuroScore II 3.1% (3.3%)
Society of Thoracic Surgeon's AVR Score 2.9% (2.9%)
All numbers are mean (standard deviation) or percentage (frequency).
⁎ Stenoses had been previously grafted, stented or were not suitable for grafting.
Table 2
Operative variables and outcomes.
Operative variables
Mechanical valve, % 31.1% (68)
Operation time, minutes 188 (60)
Cardiopulmonary bypass time, minutes 98 (30)
Cross-clamp time, minutes 74 (20)
High-sensitivity troponin, ng/L 360 (258–536)
ECG or echocardiographic changes 9.1% (20)
Outcomes
Composite morbidity 20.5% (45)
Renal failure 5.9% (13)
Stroke 1.4% (3)
Deep sternal wound infection 0.9% (2)
Ventilation N24 h 13.7% (30)
Return to theatre 6.8% (15)
New atrial ﬁbrillation 27.9% (61)
Permanent pacemaker implantation 5.9% (13)
Operation to discharge time, days 8.9 (5.1)
30-day mortality 2.7% (6)
All numbers are mean (standard deviation) or percentage (frequency).
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dicted 30-day mortality and mortality during follow-up.
Hs-TnT as a continuous parameter, or rise to N500 ng/were able to
detect composite morbidity with c-statistics of 0.626 (0.528–0.724)
and 0.612 (0.517–0.708), superior to dual criteria involving ECG and/
or echocardiographic changes. The optimal cutpoint for hs-TnT to detect
composite morbidity was 500 ng/L.
3.4. Survival
Fig. 1 shows the Kaplan–Meier survival curves over mean follow-up
of 2.3 ± 0.8 years by criteria of isolated hs-TnT rise or dual ECG orechocardiographic criteria at various hs-TnT thresholds as previously
deﬁned. Log-rank test p-values and 1-year survival for each criterion
are also shown. Hs-TnT N 140 ng/L and hs-TnT N 500 ng/L and other
criteria were associated with higher mortality during follow-up
(P b 0.05).
3.5. Multivariable analyses
Multivariable analyses for 30-day mortality and mortality during
follow-up are presented in Table 4. Neither of the pre-speciﬁed criteria
predicted 30-daymortality. Hs-TnT N500 ng/L and ECG and/or echocar-
diographic criteria was independently associated with mortality during
follow-up HR 5.23, 95% CI 1.09–25.2, P = 0.039 respectively. Hs-TnT
alone as a continuous parameter was independently associated with
30-day and medium-term mortality (P = 0.034 and P = 0.036). Other
predictors of 30-day mortality were Class IV angina (P = 0.036) and
atrial ﬁbrillation (P = 0.048). Class IV angina (P = 0.011) and atrial ﬁ-
brillation (P = 0.001) also predicted mortality during follow-up.
Table 5 lists the independent predictors of compositemorbidity. Iso-
lated troponin rise to N 500 ng/L was independently associated with
composite morbidity HR 2.56, 95% CI 1.09–5.11, P = 0.030 as was hs-
TnT as a continuous parameter (P = 0.001). Dual ECG and/or echocar-
diographic criteria were not independently associated with composite
morbidity. Other predictors of composite morbidity included NYHA
Class IV (P=0.036), active infective endocarditis (P=0.003), extra car-
diac arteriopathy (P= 0.035) and impaired ejection fraction b45% (P=
0.018).
4. Discussion
This study has several important novel ﬁndings. First, hs-
TnT N 500 ng/L and ECG and/or echocardiographic changes was inde-
pendently associated with mortality during follow-up but not 30-day
mortality. Second, hs-TnT N 140 ng/L and ECG and/or echocardiographic
criteria was not associatedwithmortality at either time point. Third, hs-
TnT alone as a continuous parameter was an independent predictor of
all three pre-speciﬁed outcomes of interest (30 daymortality, mortality
during follow-up and composite morbidity).
4.1. Isolated elevation of high-sensitivity troponin
Some, [8,10] but not all [9] studies have reported troponins to be
independently associated with mortality and/or morbidity after AVR.
Several studies have reported that post-operative troponin I or T as a
single test and as a continuous parameter predicts short and long-
term mortality in cardiac surgery cohorts, made up predominantly or
Table 3
Receiver-operating characteristic analyses.
Criteria 30-day mortality Mortality during follow-up Composite morbidity
hsTnT 0.752 (0.486–1.00) 0.615 (0.422–0.808) 0.626 (0.528–0.724)
ECG/echo criteria 0.710 (0.490–0.930) 0.584 (0.455–0.713) 0.516 (0.473–0.559)
hsTnT + ECG/echo 0.816 (0.521–1.00) 0.632 (0.427–0.838) 0.610 (0.508–0.712)
hsTnT N 140 ng/L 0.507 (0.275–0.739) 0.507 (0.341–0.674) 0.509 (0.415–0.602)
hsTnT N 500 ng/L 0.682 (0.461–0.904) 0.555 (0.383–0.727) 0.612 (0.517–0.708)
hsTnT N 630 ng/L 0.746 (0.523–0.969) 0.621 (0.443–0.799) 0.606 (0.507–0.704)
hsTnT N 140 ng/L + ECG/echo 0.710 (0.458–0.962) 0.584 (0.402–0.766) 0.516 (0.422–0.609)
hsTnT N 500 ng/L + ECG/echo 0.653 (0.388–0.917) 0.569 (0.386–0.751) 0.509 (0.603–0.415)
ECG = electrocardiogram; hsTnT = high-sensitivity troponin T.
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creatine kinase-MB and the ECG alone [3–7,16].
Several studies have reported varying optimal cut-points for isolated
troponin rise for detectingmortality after CABG between 7.8–170 times
URL [4,17–19]. One study reported an optimal cut-point for a troponin I
assay in aortic or mitral valve surgery at 15.5 times URL, slightly higher
than the corresponding optimal cut-point of 13 times URL for CABG in
the same study [8]. We found higher hs-TnT levels post-operatively
with AVR compared with isolated CABG on average (median 360 ng/L
vs 339 ng/L at our centre [3]. This may reﬂect the presence of more
left ventricular hypertrophy in aortic stenosis. However, the only inde-
pendent association was hs-TnT N500 ng/L alone predicting composite
morbidity, similar to what we found in patients undergoing CABG [3].Fig. 1. Kaplan–Meier survival curves for myocardial infarction criteria a) hs-TnT N 140 ng/L, b)
TnT N 500 ng/L and ECG and/or echocardiographic criteria. Log-rank test p-values and 1-year s4.2. Dual high-sensitivity troponin T and ECG and/or echocardiographic
criteria
ECG and/or echocardiographic criteria alone in our AVR cohort was
not independently associated with mortality or morbidity, in contrast
to our ﬁndings in patients undergoing CABG [3]. Combining this with
hs-TnT elevation as dual criteria, which has not been previously investi-
gated in the context of valve surgery, added incremental predictive
power for mortality as demonstrated in our ROC analysis.
Despite the above, none of the pre-speciﬁed hs-TnT thresholds
as with dual criteria predicted 30-day mortality. However hs-
TnT N 500 ng/L + ECG and/or echocardiographic changes predicted
mortality during follow-up. This is 10 times 99th percentile URL ashs-TnT N 500 ng/L, c) hs-TnT N 140 ng/L and ECG and/or echocardiographic criteria, d) hs-
urvival are shown.
Table 4
Multivariable analyses of mortality.
Predictors Odds/hazards
ratio
95% conﬁdence
interval
P-value
30-day mortality
Canadian Cardiovascular
Society Class IV
4.80 1.11–20.8 0.036
Atrial ﬁbrillation 4.48 1.04–19.3 0.048
No. of diseased coronary vessels 3.73 1.01–13.9 0.050
hsTnT per 100 ng/L 1.46 1.03–2.06 0.034
ECG/echo 7.76 0.68–88.7 0.099
hsTnT N 140 ng/L – – 0.999
hsTnT N 500 ng/L 2.94 0.329–26.28 0.335
hsTnT N 140 ng/L + ECG/echo 7.76 0.68–88.7 0.099
hsTnT N 500 ng/L + ECG/echo 6.83 0.332–140 0.043
Mortality during follow-up
Canadian Cardiovascular
Society Class IV
1.67 1.13–2.49 0.011
Atrial ﬁbrillation 8.12 2.29–28.8 0.001
hsTnT per 100 ng/L 1.18 1.04–1.34 0.034
ECG/echo 3.43 0.892–13.2 0.073
hsTnT N 140 ng/L – – 0.989
hsTnT N 500 ng/L 1.08 0.307–3.82 0.902
hsTnT N 140 ng/L + ECG/echo 3.43 0.893–13.2 0.073
hsTnT N 500 ng/L + ECG/echo 5.23 1.09–25.2 0.039
ECG = electrocardiogram; hsTnT = high-sensitivity troponin T.
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and 35 times the URL for hs-TnT.
4.3. Clinical implications
The results of the study suggest that in patients undergoing AVR, hs-
TnT should bemeasured routinely pre-operatively and post-operatively
at 12–24 h in patientswithout recentMI or elevated preoperative levels.
ECGs should be routinely performed pre-operatively and post-
operatively and echocardiography when clinically indicated. Future
studies are required to assess the diagnoses of MI when pre-operative
levels of hsTnT are elevated, but stable or falling [1] and to conﬁrm op-
timal cutpoints of hs-TnT with or without ECG/echocardiographic
criteria in larger prospective cohort. Interventions that may reduce the
frequency and/or worse prognosis of patients with peri-operative MI
will also need to be tested.
4.4. Limitations
This is a single-centre, retrospective observational study with 2.3
year follow-up. Themoderate cohort sizemeant that the numbers of ad-
verse events limits the power for analyses. Patients with a recent MI
were excluded as elevated troponin levels would confound the
interpretation of the post-operative levels. Also we excluded patients
with pre-operative hsTnT levels N 14 ng/mL. Echocardiography wasTable 5
Multivariable analyses of composite morbidity.
Predictors Odds ratio 95% conﬁdence interval P-value
NYHA IV 3.39 1.08–10.6 0.036
Active infectious endocarditis 8.80 2.05–37.8 0.003
Extracardiac arteriopathy 3.69 1.10–12.4 0.035
Ejection fraction b45% 2.98 1.21–7.35 0.018
hsTnT per 100 ng/L 1.15 1.06–1.26 0.001
ECG/echo 1.89 0.467–7.60 0.373
hsTnT N 140 ng/L – – 0.999
hsTnT N 500 ng/L 2.56 1.09–5.11 0.030
hsTnT 140 ng/L + ECG/echo 1.88 0.466–7.59 0.375
hsTnT 500 ng/L + ECG/echo 3.24 0.340–30.8 0.307
ECG= electrocardiogram; hsTnT= high-sensitivity troponin T. NYHA=New York Heart
Association Functional Classiﬁcation.performedwhen clinically indicated and routinely in a proportion of pa-
tients (31.5%)when logistically possible. Other forms of cardiac imaging
were not performed routinely.
5. Conclusion
This study shows that the use of hs-TnTwith a cutpoint of N 500 ng/L
(10 times coefﬁcient of variation of 10% for 4th generation troponin T
applied to hs-TnT and 35 times 99th percentile URL for hs-TnT) with
ECG and/or echocardiographic changes predicts medium-termmortali-
ty after AVR. Hs-TnT as a continuous parameter was also independently
associated with 30-daymortality, mortality during follow-up, and com-
posite morbidity.
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